About the Company
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib (trade name Tavalisse) Linzagolix Mitiglinide (Glufast) Remogliflozin etabonate Silodosin (Urief) Tranilast (Rizaben) In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on CG Oncology, Inc.
CG Oncology’s Q2 2025: Clinical Advances and Legal Wins
CG Oncology, Inc. ( ($CGON) ) has released its Q2 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - ...
A First Take On CG Oncology (NASDAQ:CGON) | Seeking Alpha
CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology ...
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -15.38% and 90.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know ... - Nasdaq
CG Oncology, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...
Why CG Oncology (CGON) Stock Is Down 9% - Benzinga
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.
CG Oncology Announces Closing of Public Offering and Full Exercise of ...
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...
Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy ...
CG Oncology, Inc. (NASDAQ:CGON) has $540.7 million in cash and cash equivalents and marketable securities as of September 30, 2024.
Q1 Earnings Forecast for CG Oncology Issued By HC Wainwright
CG Oncology Stock Down 8.2 % NASDAQ CGON opened at $17.20 on Thursday. The firm has a market cap of $1.31 billion, a P/E ratio of -12.11 and a beta of 1.24. The company’s 50 day moving average ...
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual ...
Contacts Investor Relations Bing Kung CG Oncology IR@cgoncology.com Media Kimberly Ha KKH Advisors (917) 291-5744 kimberly.ha@kkhadvisors.com Source: CG Oncology Inc. 2024 GlobeNewswire, Inc.
Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This ...
CG Oncology, Inc. (NASDAQ:CGON) is a company specializing in oncolytic immunotherapy, focusing on developing and commercializing bladder-sparing treatments for bladder cancer patients.
Similar Companies
Loading the latest forecasts...